Does 2.5mg Mounjaro Work for Weight Loss?

2.5mg is a tolerability dose: it exists to reduce early side effects like nausea, not to be the final therapeutic dose, the prescriber will typically increase it after four weeks.
Both GIP and GLP-1 receptors: tirzepatide activates two gut-hormone pathways involved in appetite and blood-sugar regulation, which distinguishes it from single-agonist medicines.
Weight loss grows with dose: in SURMOUNT-1, participants reaching 15mg saw average body-weight reductions of around 20–21% over 72 weeks, the starter dose contributes to that trajectory, it isn't the ceiling.
Side effects are often most noticeable early: nausea, loose stools and fatigue are common in the first weeks and generally ease as the body settles; a slow start is the design, not a flaw.

The 2.5mg dose of Mounjaro does work — but not in the way most people expect. At this stage, the medicine's job is to let your body adjust to tirzepatide, not to deliver the full appetite-suppressing effect. Weight loss at 2.5mg tends to be modest; the meaningful results build as your prescriber increases the dose over the following months. Mounjaro is a prescription-only medicine, so a clinical assessment decides whether it's appropriate for you — but understanding what the starter dose is actually doing helps set realistic expectations from the start.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the 2.5mg dose is doing, and what comes next

Why does Mounjaro start at such a low dose?

A question our prescribers hear most weeks: "I've been on 2.5mg for two weeks and I've barely lost anything, is it working?" The honest answer is yes, just not in the way that shows on the scales yet.

Tirzepatide activates both the GIP and GLP-1 receptors, two gut-hormone pathways that influence hunger, fullness and how quickly food leaves the stomach. At therapeutic doses, that dual action can substantially reduce appetite. But those same mechanisms, when introduced too quickly, cause the nausea and gastrointestinal discomfort that put people off continuing.

The 2.5mg starter exists to let the body become familiar with the medicine, it settles the gut response so that by the time the dose increases, most people find they tolerate it much better. Four weeks at this level is standard before a prescriber considers moving up. The full tirzepatide treatment overview explains how the titration schedule works in context, if you want the bigger picture. Think of the first pen as adjustment, not treatment in full.

Does 2.5mg Mounjaro actually cause weight loss?

Some people do lose weight at 2.5mg, appetite is suppressed to a degree even at the lowest dose, and eating slightly less over four weeks can move the scales. Others notice almost no change. Both outcomes are normal and neither predicts how well the medicine will perform as the dose increases.

The evidence base for Mounjaro comes from the SURMOUNT-1 trial, published in the New England Journal of Medicine, which enrolled 2,539 adults with obesity and found average body-weight reductions of around 20–21% at 15mg over 72 weeks. That figure reflects the full treatment course, the titration journey matters as much as the destination dose.

At 2.5mg alone, the appetite effect is partial. Gastric emptying slows a little; hunger signals shift a little. For most people, meaningful appetite reduction becomes noticeable at 5mg and above. If you want a closer look at whether 2.5mg Mounjaro is doing its job during those early weeks, that's worth reading before drawing any conclusions. If you're curious how results change at the next stage, the detail on what 5mg does differently is worth reading alongside this.

What side effects are most common at the 2.5mg stage?

The most frequently reported side effects in the early weeks are gastrointestinal: nausea, loose stools, constipation, indigestion and burping. Fatigue and mild headache are also common. They tend to peak in the first few days after a dose, then ease, and because 2.5mg is the gentlest introduction, many people find this is the stage where side effects are most manageable.

The NHS tirzepatide medicines page lists the full side-effect profile and gives clear guidance on which symptoms warrant a call to a clinician. Staying well hydrated helps; eating smaller, lower-fat meals in the early days reduces nausea for most people.

One thing to be aware of if you take an oral contraceptive: MHRA guidance advises using an additional non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because absorption of the pill may be affected. There's more on Mounjaro and birth control if this applies to you.

Should you ask for a dose increase sooner if results feel slow?

Not unilaterally, that's a clinical decision, not a personal one. The four-week minimum at each stage isn't arbitrary; it gives the medicine time to reach steady-state levels and gives the body time to adapt. Rushing the titration tends to increase side effects without meaningfully accelerating weight loss.

If after several months at the highest tolerated dose the results haven't reached a clinically meaningful level, NICE guidance on tirzepatide (TA1026) recommends reviewing whether to continue, but that review is done with a prescriber, not by adjusting doses independently. The concept of the 'golden dose' is something many patients ask about, and it's worth understanding before assuming more is always better.

Private treatment through a regulated UK pharmacy means no referral and no waiting list, provided you're clinically suitable. Patients moving from the starter pen often ask how long 5mg Mounjaro takes to work, and understanding that timeline can help set realistic expectations for the weeks ahead. If you're weighing up the options around cost and access, the weight-loss treatments page covers what a consultation involves and what treatment includes from our GPhC-registered pharmacy. The process starts with a free assessment reviewed the same day by a real prescriber, the kind of oversight that makes dose decisions safely personalised rather than one-size.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions